PL3606928T3 - Związek makrocykliczny i jego zastosowania - Google Patents

Związek makrocykliczny i jego zastosowania

Info

Publication number
PL3606928T3
PL3606928T3 PL18719390.9T PL18719390T PL3606928T3 PL 3606928 T3 PL3606928 T3 PL 3606928T3 PL 18719390 T PL18719390 T PL 18719390T PL 3606928 T3 PL3606928 T3 PL 3606928T3
Authority
PL
Poland
Prior art keywords
macrocyclic compound
macrocyclic
compound
Prior art date
Application number
PL18719390.9T
Other languages
English (en)
Inventor
Yoshito Kishi
Kazunobu Kira
Ken Ito
Original Assignee
President And Fellows Of Harvard College
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by President And Fellows Of Harvard College, Eisai R&D Management Co., Ltd. filed Critical President And Fellows Of Harvard College
Publication of PL3606928T3 publication Critical patent/PL3606928T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18719390.9T 2017-04-05 2018-04-03 Związek makrocykliczny i jego zastosowania PL3606928T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (1)

Publication Number Publication Date
PL3606928T3 true PL3606928T3 (pl) 2023-02-06

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18719390.9T PL3606928T3 (pl) 2017-04-05 2018-04-03 Związek makrocykliczny i jego zastosowania

Country Status (33)

Country Link
US (2) US11725015B2 (pl)
EP (2) EP3606928B1 (pl)
JP (4) JP6366873B1 (pl)
KR (2) KR102836514B1 (pl)
CN (2) CN110831946B (pl)
AU (2) AU2018250147B2 (pl)
CA (1) CA3056945A1 (pl)
CL (1) CL2019002854A1 (pl)
CO (1) CO2019011538A2 (pl)
DK (1) DK3606928T3 (pl)
EC (1) ECSP19075677A (pl)
ES (1) ES2931533T3 (pl)
HR (1) HRP20221385T1 (pl)
HU (1) HUE060466T2 (pl)
IL (2) IL288991B2 (pl)
JO (1) JOP20190234B1 (pl)
LT (1) LT3606928T (pl)
MA (1) MA48027B1 (pl)
MD (1) MD3606928T2 (pl)
MX (1) MX389899B (pl)
PE (1) PE20200602A1 (pl)
PH (1) PH12019502197A1 (pl)
PL (1) PL3606928T3 (pl)
PT (1) PT3606928T (pl)
RS (1) RS63755B1 (pl)
SA (1) SA519410259B1 (pl)
SG (1) SG11201908603PA (pl)
SI (1) SI3606928T1 (pl)
SM (1) SMT202200455T1 (pl)
TW (3) TWI863657B (pl)
UA (1) UA124399C2 (pl)
WO (1) WO2018187331A1 (pl)
ZA (1) ZA201906279B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
HUE060466T2 (hu) 2017-04-05 2023-03-28 Harvard College Makrociklusos vegyület és alkalmazása
BR112020000141A2 (pt) * 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
ES2974243T3 (es) * 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
CN1216051C (zh) 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CN103856986A (zh) 2007-03-07 2014-06-11 交互数字技术公司 在无线通信单元中使用的方法和装置
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
EP2663337A4 (en) 2011-01-10 2014-06-11 Harvard College METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
US9062020B2 (en) 2011-12-29 2015-06-23 Alphora Research Inc. 2-((2S,3S,4R,5R)-5-((S)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
AU2012395673A1 (en) * 2012-11-30 2014-08-14 Hangzhou Zylox Pharma Co., Ltd. Rapamycin analogs and methods for making same
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN114716453A (zh) * 2013-11-04 2022-07-08 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類縁体の合成に有用な方法
JP2017520586A (ja) * 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
WO2016179607A1 (en) 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
KR102637759B1 (ko) * 2015-07-01 2024-02-19 시그널켐 라이프사이언시즈 코포레이션 탄산 무수화효소 억제제로서의 아릴 설폰아마이드 화합물 및 이의 치료상 용도
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US20210187059A1 (en) 2017-02-20 2021-06-24 Polyphor Ag Pharmaceutical combinations for treating cancer
HUE060466T2 (hu) 2017-04-05 2023-03-28 Harvard College Makrociklusos vegyület és alkalmazása
US9938288B1 (en) * 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
US20230357286A1 (en) 2020-07-24 2023-11-09 President And Fellows Of Harvard College Ketone synthesis and applications

Also Published As

Publication number Publication date
IL269788A (en) 2019-11-28
PT3606928T (pt) 2022-12-05
HUE060466T2 (hu) 2023-03-28
IL288991B2 (en) 2023-12-01
AU2022291454B2 (en) 2024-03-28
JOP20190234A1 (ar) 2019-10-03
EP4119563A2 (en) 2023-01-18
JP6366873B1 (ja) 2018-08-08
HRP20221385T1 (hr) 2023-01-06
ECSP19075677A (es) 2020-01-31
JOP20190234B1 (ar) 2023-09-17
CN110831946A (zh) 2020-02-21
PE20200602A1 (es) 2020-03-10
MX389899B (es) 2025-03-20
US20230406863A1 (en) 2023-12-21
KR20190137121A (ko) 2019-12-10
TWI863657B (zh) 2024-11-21
TW202426457A (zh) 2024-07-01
AU2018250147A1 (en) 2019-10-03
UA124399C2 (uk) 2021-09-08
SI3606928T1 (sl) 2023-02-28
CN115093429B (zh) 2024-08-30
US12421248B2 (en) 2025-09-23
JP7168580B2 (ja) 2022-11-09
AU2018250147B2 (en) 2022-09-29
JP2022153392A (ja) 2022-10-12
ZA201906279B (en) 2021-01-27
JP7400025B2 (ja) 2023-12-18
WO2018187331A8 (en) 2018-12-06
JP7696416B2 (ja) 2025-06-20
US20210261566A1 (en) 2021-08-26
MD3606928T2 (ro) 2022-12-31
DK3606928T3 (da) 2022-11-28
TWI836643B (zh) 2024-03-21
AU2022291454A1 (en) 2023-02-16
US11725015B2 (en) 2023-08-15
RS63755B1 (sr) 2022-12-30
RU2019135531A3 (pl) 2021-09-07
JP2024028872A (ja) 2024-03-05
CL2019002854A1 (es) 2019-12-27
CO2019011538A2 (es) 2020-02-28
JP2020513021A (ja) 2020-04-30
LT3606928T (lt) 2022-12-12
ES2931533T3 (es) 2022-12-30
TW201902902A (zh) 2019-01-16
SG11201908603PA (en) 2019-10-30
TWI781163B (zh) 2022-10-21
EP3606928B1 (en) 2022-09-07
CA3056945A1 (en) 2018-10-11
SA519410259B1 (ar) 2022-09-11
IL269788B (en) 2022-01-01
EP4119563A3 (en) 2023-04-05
KR20240023674A (ko) 2024-02-22
SMT202200455T1 (it) 2023-01-13
KR102836514B1 (ko) 2025-07-22
WO2018187331A1 (en) 2018-10-11
PH12019502197A1 (en) 2020-12-07
RU2019135531A (ru) 2021-05-05
MA48027B1 (fr) 2022-12-30
BR112019020208A2 (pt) 2020-04-22
TW202321259A (zh) 2023-06-01
JP2018177774A (ja) 2018-11-15
CN110831946B (zh) 2022-06-21
MX2019011982A (es) 2019-11-08
IL288991B1 (en) 2023-08-01
CN115093429A (zh) 2022-09-23
IL288991A (en) 2022-02-01
KR102634732B1 (ko) 2024-02-13
EP3606928A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
IL271964A (en) Macrocyclic compounds and their uses
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL288991A (en) A macrocyclic compound and its uses
GB201708652D0 (en) Novel compounds and uses
GB201714745D0 (en) New compounds and uses
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
SG11202105125XA (en) Macrocyclic compound and use thereof
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
GB201810121D0 (en) Macrocyclic compounds and uses thereof
HK40032561A (en) Macrocyclic compounds and uses thereof
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses
GB201602572D0 (en) New compound and uses